Clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) is currently in clinical development for urinary incontinence in adults with neurogenic detrusor overactivity (NDO), as a result of spinal cord injury or multiple sclerosis (MS). Damage to the spinal cord, via MS or injuries, can disrupt communication between the spinal cord and bladder causing NDO. NDO increases pressure in the bladder and decreases the volume of urine the bladder can hold, leading to unexpected and frequent urine leakage (urinary incontinence).
Clostridium botulinum type A toxin-haemagglutinin complex is an injectable drug made from the bacteria that causes botulism. It can block the transmission between nerves and muscles causing a reduction in muscle activity and potentially aid the overactive muscles in the bladder that cause urinary incontinence. If licenced, clostridium botulinum type A toxin-haemagglutinin complex would provide a treatment option for adult patients with urinary incontinence from NDO, as a result of spinal cord injury or MS.
Daprodustat is in clinical development for people with anaemia associated with chronic kidney disease (CKD). Anaemia is the term used to describe a decrease in normal levels of red blood cells and is assessed by the level of haemoglobin, the protein that transports oxygen throughout the body. Anaemia commonly occurs in patients with kidney dysfunction …